Diagnostic performance of radiomics using machine learning algorithms to predict MGMT promoter methylation status in glioma patients: a meta-analysis

• Published in: Diagnostic and Interventional Radiology Vol. 27; no. 6; pp. 716 - 724
• Main Authors: Huang, Huan, Wang, Fei-fei, Luo, Shigang, Chen, Guangxiang, Tang, Guangcai
• Format: Journal Article
• Language: English
• Published: Galenos Yayinevi Tic. Ltd 01.11.2021; Turkish Society of Radiology; Galenos Publishing House
• Subjects: Algorithms; Cancer; Computer-aided medical diagnosis; Diagnosis; Gliomas; Head and Neck Imaging; Machine learning; Medical research; Medicine, Experimental; Methods; Methylation; Methyltransferases; Oncology, Experimental; Promoters (Genetics); China
• ISSN: 1305-3825; 1305-3612; 1305-3612
• DOI: 10.5152/dir.2021.21153

PURPOSE We aimed to assess the diagnostic performance of radiomics using machine learning algorithms to predict the methylation status of the [O.sup.6]-methylguanine-DNA methyltransferase (MGMT) promoter in glioma patients. METHODS A comprehensive literature search of PubMed, EMBASE, and Web of Science until 27 July 2021 was performed to identify eligible studies. Stata SE 15.0 and Meta-Disc 1.4 were used for data analysis. RESULTS A total of 15 studies with 1663 patients were included: 5 studies with training and validation cohorts and 10 with only training cohorts. The pooled sensitivity and specificity of machine learning for predicting MGMT promoter methylation in gliomas were 85% (95% CI 79%-90%) and 84% (95% CI 78%-88%) in the training cohort (n=15) and 84% (95% CI 70%-92%) and 78% (95% CI 63%-88%) in the validation cohort (n=5). The AUC was 0.91 (95% CI 0.88-0.93) in the training cohort and 0.88 (95% CI 0.85-0.91) in the validation cohort. The meta-regression demonstrated that magnetic resonance imaging sequences were related to heterogeneity. The sensitivity analysis showed that heterogeneity was reduced by excluding one study with the lowest diagnostic performance. CONCLUSION This meta-analysis demonstrated that machine learning is a promising, reliable and repeatable candidate method for predicting MGMT promoter methylation status in glioma and showed a higher performance than non-machine learning methods.